dc.contributor.author | Ianevski, Aleksandr | |
dc.contributor.author | Yao, Rouan | |
dc.contributor.author | Fenstad, Mona H. | |
dc.contributor.author | Biza, Svetlana | |
dc.contributor.author | Zusinaite, Eva | |
dc.contributor.author | Reisberg, Tuuli | |
dc.contributor.author | Lysvand, Hilde | |
dc.contributor.author | Løseth, Kirsti | |
dc.contributor.author | Landsem, Veslemøy Malm | |
dc.contributor.author | Fossum, Janne | |
dc.contributor.author | Erlandsen, Sten Even | |
dc.contributor.author | Aas, Per Arne | |
dc.contributor.author | Hagen, Lars | |
dc.contributor.author | Pettersen, Caroline Hild | |
dc.contributor.author | Tenson, Tanel | |
dc.contributor.author | Afset, Jan Egil | |
dc.contributor.author | Nordbø, Svein Arne | |
dc.contributor.author | Bjørås, Magnar | |
dc.contributor.author | Kainov, Denis | |
dc.contributor.author | Oksenych, Valentyn | |
dc.date.accessioned | 2021-04-23T07:59:22Z | |
dc.date.available | 2021-04-23T07:59:22Z | |
dc.date.created | 2020-06-19T14:40:53Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Viruses. 2020, 12 (6), . | en_US |
dc.identifier.issn | 1999-4915 | |
dc.identifier.uri | https://hdl.handle.net/11250/2739261 | |
dc.description.abstract | As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Potential Antiviral Options against SARS-CoV-2 Infection. Viruses. | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.volume | 12 | en_US |
dc.source.journal | Viruses | en_US |
dc.source.issue | 6 | en_US |
dc.identifier.doi | 10.3390/v12060642 | |
dc.identifier.cristin | 1816374 | |
dc.description.localcode | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |